ArticleCurrent medicinal chemistry2025
Assessing the Inhibitory Potential of Natural Compounds for Targeting the CrtM Proteins in Methicillin-Resistant
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
introductionThe development of Methicillin-Resistant Staphylococcus aureus (MRSA) presents a significant risk to worldwide health and necessitates the creation of novel antimicrobial approaches. The enzyme dehydrosqualene synthase (CrtM), necessary for the bacterial species
methodsTanimoto's similarity of 406,621 unique natural compounds collected from the COCONUT database was calculated using the known inhibitor of CrtM, hesperidin. Further, machine learning-based QSAR screening was performed on these natural compounds where two compounds showed promising binding with the CrtM protein (4299376 and 12897366). A binding score of -9.49 kcal/mol was found for 4299376 and 12897366, respectively, via molecular docking; this value was close to that of the control drug, hesperidin, which was -9.55 kcal/mol. Molecular dynamics simulations conducted at 30 ns and with complexes of MM/GBSA demonstrated binding free energies of -14.38 kcal/mol for 12897366 and -42.72 kcal/mol for 4299376, respectively. 4299376 was selected further for 200 ns MD simulation because of its high binding affinity and stability in the RMSD plots.
resultsAdditionally, post 200 ns MD analysis and MM/GBSA analysis showed the consistent stability and strong binding of 4299376 with CrtM (RMSD = 0.3 nm and binding free energy of -37.30 kcal/mol). Moreover, the critical residue Gln165 of CrtM was found to have a hydrogen bond with 4299376 in the 0 ns, 100 ns, and 200 ns conformation. Overall, 4299376 performed well in the PCA, free energy landscape, and per-residue decomposition, proving it is an effective CrtM binder. The free energy perturbation (FEP) analysis revealed that as the system progressed from fully bound (λ = 0) to decoupled (λ = 10), the free energy (ΔG) changed from 6.56 kT to -4.38 kT, signifying a reduction in binding free energy and implying an increase in entropy and solvation effects that stabilize the ligand in the decoupled state. This underscores the entropic contribution and solvent interactions as critical determinants in the lowering of binding free energy.
conclusionThis study concluded that 4299376 exhibits considerable therapeutic potential and could be investigated further for its potential use as an inhibitor against CrtM of S. aureus.
Indexed as
Identifiers
40033499What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.